Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Laura Vidal Boixader"'
Autor:
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, Tomasz Byrski, Patricia Pautier, Philipp Harter, Nicoletta Colombo, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Frédéric Selle, Isabelle Ray-Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Mayu Yunokawa, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Susana Banerjee, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Holger Hirte, Amnon Amit, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez De Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg
Publikováno v:
Lancet Oncology, 22, 5, pp. 620-631
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group
Contains fulltext : 241226.pdf (Publisher’s version ) (Closed access) BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with re
Autor:
Laura Vidal Boixader, Keren Rachel Moss, Jim Wahl, Jozsef Palatka, Nicholas Kenny, Kelly Kevelin Cartis, Liat Vidal
Publikováno v:
Journal of Clinical Trials.
Autor:
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedlander, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray-Coquard, Susana Banerjee, Joyce Liu, Elizabeth S Lowe, Ralph Bloomfield, Patricia Pautier, Tomasz Byrski, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault de la Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Anne Floquet, Holger Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg, Ignace Vergote
Publikováno v:
The Lancet Oncology, 18(9), 1274-1284. Lancet Publishing Group
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6905acb5cb7386782be1e6d05659ba93
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85025811245
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85025811245
Autor:
Keren Rachel Moss, Daniel Shepshelovich, Kelly K. Curtis, Vasily Andrianov, Laura Vidal Boixader, Liat Vidal-Fisher
Publikováno v:
Journal of Clinical Oncology. 37:6590-6590
6590 Background: Clinically relevant outcomes as improvements in overall survival (OS) or quality of life (QOL) should guide decision-making. The FDA encourages the implementation of patient-centric measures in clinical trials. Over the past decade a
Autor:
Keren Rachel Moss, Kelly K. Curtis, Liat Vidal, Laura Vidal Boixader, Jozsef Palatka, Nicholas Kenny
Publikováno v:
Molecular Cancer Therapeutics. 17:A088-A088
Background: In oncology drug development, prior to conduct of phase 3 registration trials, phase 2 RCTs have been conducted in many instances to provide initial evidence of a statistically significant effect on patient outcomes. However, the high ant
Publikováno v:
Journal of Clinical Oncology. 35:2543-2543
2543 Background: Trials using randomized designs have been conducted for decades to demonstrate efficacy of novel anti-cancer drugs (NACD). Recently, several NACD have shown high antitumor activity in early phase studies, prompting suggestions that N
Publikováno v:
Journal of Clinical Oncology. 34:2537-2537
2537Background: The incidence of leukemia (L) is increasing worldwide, with an estimated 350,000 people diagnosed each year. One major motivation for looking abroad for drug clinical development is...
Autor:
Mercè Brunet, Pedro Gascón, Marc Cortal, Gisela Riu, Lydia Gaba, Jose Alfon, Laura Vidal Boixader, Iván Victoria, Elvira Buxó, Mariana Gomez-Ferreria, Teresa Vilella, Pilar Paredes, Carles Domenech
Publikováno v:
Journal of Clinical Oncology. 33:2585-2585
2585 Background: ABTL0812 is a novel drug with reported preclinical activity in several tumor types. In vitro and in vivo assays have shown that ABTL0812 is an inhibitor of the Akt/mTOR pathway by ...
Autor:
Manuel Selvi, Maria Mayoral, Pilar Paredes, Francisco Aya, Laura Vidal Boixader, Pedro Gascón, Aranzazu Fernandez
Publikováno v:
Journal of Clinical Oncology. 32:e16518-e16518
e16518 Background: Metabolic tumor parameters for preoperative [18F]FDG PET/TC imaging may be a useful predictor of recurrence in patients with epithelial ovarian cancer (EOC). The aim of this stud...
Autor:
M Jesus Rubio, Laia Garrigós, Laura Vidal Boixader, Jesús García-Donas, Andrés Redondo, Isabel Bover, Eva Guerra Alia, Juan Cueva, A. Hurtado, José Antonio López-Guerrero, Elena García-Martínez, Nuria Romero, Mario Prieto, Zaida García-Casado, Ana Santaballa, Nuria Lainez, Victor Rodriguez, I. Palacio, Enrique Grande
Publikováno v:
Journal of Clinical Oncology. 32:5558-5558
5558 Background: Granulosa-cell tumors (GCTs) of the ovary are a rare entity characterized by its genomic stability, presenting a punctual mutation at the FOXL2 gene, 402C→G (C134W), in the vast ma...